liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Åvall-Lundqvist, Elisabeth
Alternative names
Publications (10 of 63) Show all publications
Lindemann, K., Gibbs, E., Åvall-Lundqvist, E., dePont Christensen, R., Woie, K., Kalling, M., . . . Kristensen, G. (2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer, 116(4), 455-463
Open this publication in new window or tab >>Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Show others...
2017 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 116, no 4, p. 455-463Article in journal (Refereed) Published
Abstract [en]

Background: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. Methods: Patients with PROC were randomised (2 : 1) to chemotherapy (weekly paclitaxel 80 mg m(-2) or four weekly pegylated liposomal doxorubicin 40 mg m(-2)) or tamoxifen 40mg daily. The primary end point was HRQoL. Secondary end points were PFS by RECIST and overall survival (OS). Results: Between March 2002 and December 2007, 156 and 82 patients were randomised to chemotherapy and tamoxifen, respectively. In the chemotherapy arm, a significantly larger proportion of patients experienced a worsening in their social functioning. There was no difference in the proportion of patients experiencing improvement of gastrointestinal symptoms. Median PFS on tamoxifen was 8.3 weeks (95% CI, 8.0-10.4) compared with 12.7 weeks (95% CI, 9.0-16.3) on chemotherapy (HR, 1.54; 95% CI, 1.16-2.05; log-rank P = 0.003). There was no difference in OS between the treatment arms. Conclusions: Patients on chemotherapy had longer PFS but experienced more toxicity and poorer HRQoL compared with tamoxifen. Control over gastrointestinal symptoms was not better on chemotherapy. These data are important for patient counselling and highlight the need to incorporate HRQoL end points in studies of PROC.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP, 2017
Keywords
platinum-resistent ovarian cancer; chemotherapy; tamoxifen; quality of life; survival; phase III
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-136169 (URN)10.1038/bjc.2016.435 (DOI)000394446600006 ()28118323 (PubMedID)
Available from: 2017-04-03 Created: 2017-04-03 Last updated: 2018-04-17
Dahm-Kähler, P., Borgfeldt, C., Holmberg, E., Staf, C., Falconer, H., Bjurberg, M., . . . Åvall-Lundqvist, E. (2017). Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).. Gynecologic Oncology, 144(1), 167-173
Open this publication in new window or tab >>Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
Show others...
2017 (English)In: Gynecologic Oncology, ISSN 0090-8258, E-ISSN 1095-6859, Vol. 144, no 1, p. 167-173Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin.

METHODS: Nation-wide population-based study of women≥18years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models.

RESULTS: Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the fallopian tube (FTC), 9% in the peritoneum (PPC) and 11% at an undesignated primary site (UPS). Estimated RS at 5-years was 37%; for FTC 54%, 40% for OC, 34% for PPC and 13% for UPS. In multivariable regression analyses restricted to women who had undergone primary or interval debulking surgery for OC, FTC and PPC, site of origin was not independently associated with survival. Significant associations with worse survival were found for advanced stages (RR 2.63, P<0.001), moderate (RR 1.90, P<0.047) and poor differentiation (RR 2.20, P<0.009), neoadjuvant chemotherapy (RR1.33, P<0.022), residual tumor (RR 2.65, P<0.001) and platinum single (2.34, P<0.001) compared to platinum combination chemotherapy.

CONCLUSION: Survival was poorer for serous cancer at UPS than for ovarian, fallopian tube and peritoneal cancer. Serous cancer at UPS needs to be addressed when reporting and comparing survival rates of ovarian cancer.

Place, publisher, year, edition, pages
Academic Press, 2017
Keywords
Ovarian cancer, Serous cancer, Survival, Cancer origin
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-133707 (URN)10.1016/j.ygyno.2016.10.039 (DOI)000392367000030 ()27817932 (PubMedID)2-s2.0-85005865079 (Scopus ID)
Note

Funding agencies: Swedish Cancer Society; Cancer Society in Stockholm

Available from: 2017-01-07 Created: 2017-01-07 Last updated: 2018-05-02Bibliographically approved
Stålberg, K., Kjölhede, P., Bjurberg, M., Borgfeldt, C., Dahm-Kahler, P., Falconer, H., . . . Högberg, T. (2017). Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register studyOn behalf of the Swedish Gynecological Cancer Group. International Journal of Cancer, 140(12), 2693-2700
Open this publication in new window or tab >>Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register studyOn behalf of the Swedish Gynecological Cancer Group
Show others...
2017 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 140, no 12, p. 2693-2700Article in journal (Refereed) Published
Abstract [en]

The role of lymphadenectomy in the management of early endometrial cancer remains controversial. In the recent ESMO-ESGO-ESTRO guidelines, lymphadenectomy is recommended for patients with endometrioid adenocarcinoma Grade 3 with deep myometrial invasion, but complete agreement was not achieved. In Sweden, DNA aneuploidy has been included as a high-risk factor. The aim of our study was to evaluate the impact of tumor histology, FIGO grade, DNA ploidy and myometrial invasion (MI) on occurrence of lymph node metastasis (LNM) in patients with endometrial cancer. The study design is a retrospective cohort study based on prospectively recorded register data. Endometrial cancer patients registered in the Swedish Quality Registry for Gynecologic Cancer 2010-2015 with FIGO Stages I-III and verified nodal status were included. Data on DNA ploidy, histology, FIGO grade and MI were included in multivariable log-binomial regression analyses with LNM as dependent variable. 1,165 cases fulfilled the inclusion criteria. The multivariable analyses revealed increased risk of LNM in patients with tumors with MI50% (risk ratio [RR]=4.1; 95% confidence interval [CI] 3.0-5.6), nonendometrioid compared to endometrioid histology (RR 1.8; CI 1.4-2.4) and FIGO Grade 3 compared to Grade 1-2 tumors (RR 1.5; CI 1.1-2.0). No statistically significant association between DNA ploidy status and LNM was detected. This population-based, nation-wide study in women with endometrial cancer confirms a strong association between MI50%, nonendometrioid histology and FIGO Grade 3, respectively, and LNM. DNA ploidy should not be included in the preoperative decision making of removing nodes or not. Whats new? Whether lymphadenectomy is beneficial for women with endometrial cancer remains uncertain. Moreover, additional studies are needed to explore factors that reliably predict lymph node metastasis (LNM). Here, multiple factors, including tumor histology, grade of differentiation and DNA aneuploidy, were evaluated for associations with LNM risk in women with endometrial cancer and verified lymph node status. Most significantly, deep myometrial invasion in tumors increased LNM risk fourfold, whereas DNA ploidy had essentially no impact on LNM risk. The findings confirm the predictive relevance of myometrial invasion, histology and grade reported in previous single-center and multicenter studies.

Place, publisher, year, edition, pages
John Wiley & Sons, 2017
Keywords
endometrial cancer; lymph node metastases; risk factor; epidemiology
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-137584 (URN)10.1002/ijc.30707 (DOI)000400158800008 ()28340503 (PubMedID)2-s2.0-85017534425 (Scopus ID)
Note

Funding Agencies|Swedish Cancer Society

Available from: 2017-05-22 Created: 2017-05-22 Last updated: 2018-05-02Bibliographically approved
Apellániz-Ruiz, M., Tejero, H., Inglada-Pérez, L., Sánchez-Barroso, L., Gutiérrez-Gutiérrez, G., Calvo, I., . . . Rodriguez-Antona, C. (2017). Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy.. Clinical Cancer Research, 23(5), 1227-1235
Open this publication in new window or tab >>Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy.
Show others...
2017 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 23, no 5, p. 1227-1235Article in journal (Refereed) Published
Abstract [en]

PURPOSE: Neuropathy is the dose limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, the major causes for inter-individual differences remain unexplained. In this study we identified genetic markers associated with paclitaxel-induced neuropathy through massive sequencing of candidate genes.

EXPERIMENTAL DESIGN: We sequenced the coding region of 4 EPHA genes, 5 genes involved in paclitaxel pharmacokinetics and 30 Charcot-Marie-Tooth genes, in 228 cancer patients with no/low neuropathy or high grade neuropathy during paclitaxel treatment. An independent validation series included 202 paclitaxel-treated patients. Variation-/ gene-based analyses were used to compare variant frequencies among neuropathy groups and Cox regression models were used to analyze neuropathy evolution along treatment.

RESULTS: Gene-based analysis identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy. Low frequency non-synonymous variants in EPHA6 were present exclusively in patients with high neuropathy and all affected the ligand binding domain. Accumulated dose analysis in the discovery series showed a significantly higher neuropathy risk for EPHA5/6/8 low-frequency non-synonymous variant carriers (HR=14.60, 95%CI=2.33-91.62, P=0.0042) and an independent cohort confirmed an increased neuropathy risk (HR=2.07, 95%CI=1.14-3.77, P=0.017). Combining the series gave an estimated 2.50-fold higher risk of neuropathy (95%CI=1.46-4.31; P=9.1x10(-4)).

CONCLUSION: This first study sequencing EPHA genes revealed that low frequency variants in EPHA6, EPHA5 and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy. Furthermore, EPHAs neuronal injury repair function suggests that these genes might constitute important neuropathy markers for many neurotoxic drugs.

Place, publisher, year, edition, pages
American Association of Cancer Research, 2017
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-133683 (URN)10.1158/1078-0432.CCR-16-0694 (DOI)000396015600014 ()27582484 (PubMedID)2-s2.0-85014608950 (Scopus ID)
Note

Funding agencies: Spanish Ministry of Economy and Competiveness [SAF2015-64850-R]; Severo Ochoa Excellence Programme [SEV-2011-0191]; Fundacion AECC; Swedish Cancer Society; Swedish Research Council; LiU Cancer

Available from: 2017-01-07 Created: 2017-01-07 Last updated: 2018-04-17Bibliographically approved
Corvigno, S., Wisman, G. B., Mezheyeuski, A., van der Zee, A. G. J., Nijman, H. W., Åvall-Lundqvist, E., . . . Dahlstrand, H. (2016). Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. OncoTarget, 7(14), 18573-18584
Open this publication in new window or tab >>Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival
Show others...
2016 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 7, no 14, p. 18573-18584Article in journal (Refereed) Published
Abstract [en]

Inter- and intra-patient variations in tumor microenvironment of serous ovarian cancer are largely unexplored. We aimed to explore potential co-regulation of tumor stroma characteristics, analyze their concordance in primary and metastatic lesions, and study their impact on survival. A tissue microarray (TMA) with 186 tumors and 91 matched metastases was subjected to immunohistochemistry double staining with endothelial cell marker CD34 and fibroblast and pericyte markers alpha-SMA, PDGF beta R and desmin. Images were digitally analyzed to yield "metrics" related to vasculature and stroma features. Intra-case analyses showed that PDGF beta R in perivascular cells and fibroblasts were strongly correlated. Similar findings were observed concerning `-SMA. Most stroma characteristics showed large variations in intra-case comparisons of primary tumors and metastasis. Large PDGF beta R-positive stroma fraction and high PDGF beta FR positive perivascular intensity were both significantly associated with shorter survival in uni- and multi-variate analyses (HR 1.7, 95% CI 1.1-2.5; HR 1.7, 95% CI 1.1-2.8). In conclusion, we found PDGF beta R- and alpha-SMA-expression to be largely independent of each other but concordantly activated in perivascular cells and in fibroblasts within the primary tumor. Stromal characteristics differed between primary tumors and metastases. PDGF beta R in perivascular cells and in fibroblasts may be novel prognostic markers in serous ovarian cancer.

Place, publisher, year, edition, pages
Impact Journals LLC, 2016
Keywords
cancer associated fibroblasts; pericytes; prognosis; serous ovarian cancer; tumor microenvironment
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:liu:diva-128961 (URN)10.18632/oncotarget.7613 (DOI)000375699000101 ()26918345 (PubMedID)2-s2.0-84975471331 (Scopus ID)
Note

Funding Agencies|Cancer Research Foundations of Radiumhemmet; Swedish Research Council (STARGET Linne grant); Swedish Cancer Society; Stockholm City Council

Available from: 2016-06-09 Created: 2016-06-07 Last updated: 2018-01-10Bibliographically approved
Wangsa, D., Akhter Chowdhury, S., Ryott, M., Michael Gertz, E., Elmberger, G., Auer, G., . . . Heselmeyer-Haddad, K. (2016). Phylogenetic analysis of multiple FISH markers in oral tongue squamous cell carcinoma suggests that a diverse distribution of copy number changes is associated with poor prognosis. International Journal of Cancer, 138(1), 98-109
Open this publication in new window or tab >>Phylogenetic analysis of multiple FISH markers in oral tongue squamous cell carcinoma suggests that a diverse distribution of copy number changes is associated with poor prognosis
Show others...
2016 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 138, no 1, p. 98-109Article in journal (Refereed) Published
Abstract [en]

Oral tongue squamous cell carcinoma (OTSCC) is associated with poor prognosis. To improve prognostication, we analyzed four gene probes (TERC, CCND1, EGFR and TP53) and the centromere probe CEP4 as a marker of chromosomal instability, using fluorescence in situ hybridization (FISH) in single cells from the tumors of sixty-five OTSCC patients (Stage I, n=15; Stage II, n=30; Stage III, n=7; Stage IV, n=13). Unsupervised hierarchical clustering of the FISH data distinguished three clusters related to smoking status. Copy number increases of all five markers were found to be correlated to non-smoking habits, while smokers in this cohort had low-level copy number gains. Using the phylogenetic modeling software FISHtrees, we constructed models of tumor progression for each patient based on the four gene probes. Then, we derived test statistics on the models that are significant predictors of disease-free and overall survival, independent of tumor stage and smoking status in multivariate analysis. The patients whose tumors were modeled as progressing by a more diverse distribution of copy number changes across the four genes have poorer prognosis. This is consistent with the view that multiple genetic pathways need to become deregulated in order for cancer to progress. Whats new? Oral tongue squamous cell carcinoma (OTSCC) is a rare head and neck cancer that typically is asymptomatic in early stages. Hence, in order to improve prognosis in OTSCC, predictive biomarkers that are independent of tumor stage must be identified. Here, using four fluorescence in situ hybridization (FISH) gene probes and the software FISHtrees, phylogenetic tree models of tumor progression in OTSCC patients were constructed. Analyses of the models showed that the more diverse the changes within the four marker genes, the worse the outcome in OTSCC. The markers predicted survival independent of smoking behavior and tumor stage.

Place, publisher, year, edition, pages
John Wiley & Sons, 2016
Keywords
oral tongue cancer, FISH, genetic markers, phylogenetic modeling, HPV
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-122643 (URN)10.1002/ijc.29691 (DOI)000363203600014 ()26175310 (PubMedID)2-s2.0-84944276406 (Scopus ID)
Note

Funding Agencies|National Institutes of Health (NIH), National Cancer Institute, National Library of Medicine (Intramural Research Program) NIH Extramural grants [1R01CA140214, 1R01AI076318]; Swedish Cancer Society (Cancerfonden); Cancer Society of Stockholm (Cancerforeningen); Laryngfonden; Karolinska Institutet

Available from: 2015-11-16 Created: 2015-11-13 Last updated: 2017-05-12Bibliographically approved
Högberg, T., Bergfeldt, K., Borgfeldt, C., Holmberg, E. & Åvall Lundqvist, E. (2015). Hopp om förbättring av överlevnad i ovarialcancer. Läkartidningen, 112(50), 2281-3
Open this publication in new window or tab >>Hopp om förbättring av överlevnad i ovarialcancer
Show others...
2015 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 112, no 50, p. 2281-3Article in journal (Refereed) Published
Abstract [en]

Ovarian cancer is the most common cause of death from a gynecologic cancer. Every year around 700 women contracts ovarian cancer in Sweden. The overall survival is among the highest in Europe, but still long term relative survival is only 46%. It is a long-held myth that ovarian cancer is a disease without symptoms. Almost 90% of women have symptoms, even in the early stages. Symptoms that should arise suspicion of ovarian cancer and initiate diagnostic work-up are continuous abdominal extension, early feeling of satiety, pelvic or abdominal pain, urinary urge and postmenopausal bleeding. Women's awareness of symptoms and willingness to seek medical advice and the organization of the health care system are important factors determining cancer survival. Ovarian cancer is a heterogeneous group of diseases with different tumor traits and prognosis. Personalized medicine and preventive measures recognizing recent knowledge about tumor biology will positively affect survival.

Abstract [sv]

Ovarialcancer har högst mortalitet bland gynekologiska cancersjukdomar. I Sverige insjuknar årligen ca 700 patienter. Överlevnaden är bland de högsta i Europa, men på en låg nivå, 46 procent.

Nästan 90 procent av kvinnorna har symtom även i tidigt stadium.

Symtom som ska väcka misstanke om ovarialcancer är ihållande utspänd buk, tidig mättnadskänsla, bäcken- eller buksmärta, ökande urinträngningar och postmenopausal blödning.

Kvinnors benägenhet att söka sjukvård och sjukvårdens organisation bidrar till canceröverlevnad.

Ovarialcancer sammanfattar flera sjukdomar med skilda tumörkarakteristika och prognos. Individualiserad behandling och preventiva åtgärder utifrån denna nyvunna kunskap kan komma att inverka positivt på överlevnaden.

Place, publisher, year, edition, pages
Läkartidningen Förlag AB, 2015
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-125271 (URN)26646961 (PubMedID)
Available from: 2016-02-18 Created: 2016-02-18 Last updated: 2017-05-12Bibliographically approved
Kjölhede, P., Dahm-Kähler, P., Tholander, B. & Åvall Lundqvist, E. (2015). Individualiserad behandling vid ovarialcancer kan bli möjlig. Läkartidningen, 112(50), 2281-3
Open this publication in new window or tab >>Individualiserad behandling vid ovarialcancer kan bli möjlig
2015 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 112, no 50, p. 2281-3Article in journal (Refereed) Published
Abstract [en]

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in developed countries. Several promising steps toward individualized therapy have been taken recently due to increased knowledge of molecular biology. Multidisciplinary conferences for treatment planning and the centralization to tertiary surgical centers improve quality of surgery and survival. The primary treatment of EOC is radical surgery followed by adjuvant chemotherapy with carboplatin and paclitaxel. Bevacizumab added to the chemotherapy and used as maintenance treatment is standard in the primary treatment of patients with residual tumor or inoperable patients. The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy. BRCA testing should be offered to women with EOC. In platinum-resistant recurrence addition of bevacizumab to chemotherapy should be considered.

Abstract [sv]

Ovarialcancer har högst mortalitet bland gynekologiska cancersjukdomar. I Sverige insjuknar årligen ca 700 patienter. Överlevnaden är bland de högsta i Europa, men på en låg nivå, 46 procent.Nästan 90 procent av kvinnor-na har symtom även i tidigt stadium.Symtom som ska väcka misstanke om ovarialcancer är ihållande utspänd buk, tidig mättnadskänsla, bäcken- eller buksmärta, ökande urinträngningar och postmenopausal blödning.Kvinnors benägenhet att söka sjukvård och sjukvårdens organisation bidrar till canceröverlevnad.Ovarialcancer sammanfattarflera sjukdomar med skilda tumörkarakteristika och prognos. Individualiserad behandling och preventiva åtgärder utifrån denna nyvunna kunskap kan komma att inverka positivt på överlevnaden.

National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-125273 (URN)26646960 (PubMedID)
Available from: 2016-02-18 Created: 2016-02-18 Last updated: 2017-05-12Bibliographically approved
Apellaniz-Ruiz, M., Sanchez-Barroso, L., Gutierrez-Gutierrez, G., Sereno, M., Garcia-Donas, J., Åvall Lundqvist, E., . . . Rodriguez-Antona, C. (2015). Letter: Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel-Letter in CLINICAL CANCER RESEARCH, vol 21, issue 13, pp 3092-3093 [Letter to the editor]. Clinical Cancer Research, 21(13), 3092-3093
Open this publication in new window or tab >>Letter: Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel-Letter in CLINICAL CANCER RESEARCH, vol 21, issue 13, pp 3092-3093
Show others...
2015 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 21, no 13, p. 3092-3093Article in journal, Letter (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
American Association for Cancer Research, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-120275 (URN)10.1158/1078-0432.CCR-14-1885 (DOI)000357337200026 ()26133776 (PubMedID)
Available from: 2015-07-24 Created: 2015-07-24 Last updated: 2017-12-04
Åvall Lundqvist, E. (2015). Paradigmskifte för gynekologisk cancer. Läkartidningen, 112(50), 2271
Open this publication in new window or tab >>Paradigmskifte för gynekologisk cancer
2015 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 112, no 50, p. 2271-Article in journal (Refereed) Published
Abstract [sv]

Med ökad förståelse för bakomliggande mekanismer har ett genombrott skett vad gäller behandling och förståelse av gynekologisk cancer. I år godkändes den första målriktade behandlingen vid gynekologisk cancer, och därmed blir individualiserad behandling en realitet.

Place, publisher, year, edition, pages
Läkartidningen Förlag AB, 2015
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-125269 (URN)26646962 (PubMedID)
Available from: 2016-02-18 Created: 2016-02-18 Last updated: 2017-05-12Bibliographically approved
Organisations

Search in DiVA

Show all publications